Alexion Pharmaceuticals (ALXN) : The money flow analysis of Alexion Pharmaceuticals (ALXN) indicates a $41.41 million of outflow was on downticks, whereas, the investors on Friday gobbled up stocks worth $54.13 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.31 and so was the total money flow at $12.71 million. A solid up-down ratio of 10.29 in block trades indicates that the investors are accumulating the stock on weakness. The bulls lapped up $13.01 million worth of block trades on upticks. Only $1.26 million worth of the stock exchanged hands on downticks. The money flow was $11.75 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Alexion Pharmaceuticals (ALXN), pushing it down by -1.18% for the day. The stock slid $1.5 and traded at $125.8 during the day. Nonetheless, the stock is 0.18% over the previous weeks close.
Alexion Pharmaceuticals (ALXN) : Currently there are 15 street experts covering Alexion Pharmaceuticals (ALXN) stock. The most bullish and bearish price target for the stock is $221 and $145 respectively for the short term. The average price target of all the analysts comes to $189.73. The estimated standard deviation from the target is $21.96.
Alexion Pharmaceuticals (NASDAQ:ALXN): On Fridays trading session , Opening price of the stock was $127.74 with an intraday high of $127.98. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $125.34. However, the stock managed to close at $125.8, a loss of 1.18% for the day. On the previous day, the stock had closed at $127.3. The total traded volume of the day was 1,381,823 shares.
In a related news, Moriarty John B, officer (EVP & General Counsel) of Alexion Pharmaceuticals Inc, unloaded 918 shares at an average price of $135.72 on June 13, 2016. The total amount of the transaction was worth $124,591, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.